The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Anyone who follows Jim Cramer's stock picks knows that he loves the biotech sector. Especially NPS Pharmaceuticals, up 45 percent in the past month. Wowzer!
On Sunday, Ireland-based Shire PLC agreed to acquire NPS Pharma for an all cash deal of $5.2 billion, or $46 a share.
Cramer thinks this is a huge deal. "It confirms the strength of one of my absolute favorite themes, biotech companies that develop what are known as orphan drugs to treat ultra-rare diseases," he said.
Essentially, a deal this size shows that the big-dog pharma companies are willing to pay up for a little orphan company like NPS. A good sign.
NPS has seen some success with its drug Gattex, which treats short-bowel syndrome. Short-bowel is a condition where the intestines are unable to absorb nutrients from food, thus resulting in feeding patients from a tube. Gattex has shown promising results, ultimately aiming to get patients off feeding tube dependence.
Cramer started recommending NPS back in October 2012, when the stock was trading at $8.24. It now trades at $45, and the "Mad Money" host said it's time to ring the register on this hot biotech play.
To learn more, Cramer sat down with NPS Pharmaceuticals CEO Dr. Francois Nader.
"What we do in the rare-disease business is select an indication where there is no other treatment, where there is a huge medical need and limited number of patients. Gattex is one of those drugs where it will bring value to the patients," Nader said.
The CEO explained that what makes NPS unique is the critical need to find patients individually. There are approximately 3,000 to 5,000 chronic patients of short-bowel syndrome in the U.S.
Read more from Mad Money with Jim Cramer
Cramer Remix: Last chance to buy this
Cramer: Low wages are good for investors
Cramer: New ball game for earnings
"Finding them is just the first step. And then we have to walk them through a process of reimbursement and then train them on the drug. So really the rare-disease business is dealing with one patient at a time," he added.
From an investing perspective, Nader warned that it will be a tumultuous but prosperous ride.
"It will be a bumpy ride, and it's absolutely not a linear growth. Remember, it is one patient at a time; every patient counts. So some quarters you have many more patients and others you don't. What you need to look at is the trend, and not really at the point-per-point basis," he said.